Dimensional Fund Advisors LP Eagle Pharmaceuticals, Inc. Transaction History

Dimensional Fund Advisors LP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$4.26 - $6.51 $321,229 - $490,893	-75,406 Reduced 30.59%	171,091 $896,000
Q4 2023 Feb 07, 2024	SELL	$4.63 - $15.21 $158,304 - $520,045	-34,191 Reduced 12.18%	246,497 $1.29 Million
Q3 2023 Nov 09, 2023	SELL	$15.21 - $22.88 $1.82 Million - $2.74 Million	-119,811 Reduced 29.92%	280,688 $4.43 Million
Q2 2023 Aug 09, 2023	SELL	$17.74 - $31.87 $1.03 Million - $1.84 Million	-57,813 Reduced 12.61%	400,499 $7.79 Million
Q1 2023 May 12, 2023	BUY	$25.06 - $34.09 $2.72 Million - $3.71 Million	108,706 Added 31.09%	458,312 $13 Million
Q4 2022 Feb 09, 2023	SELL	$24.98 - $39.77 $153,701 - $244,704	-6,153 Reduced 1.73%	349,606 $10.2 Million
Q3 2022 Nov 10, 2022	BUY	$26.42 - $47.12 $1.01 Million - $1.79 Million	38,083 Added 11.99%	355,759 $9.4 Million
Q2 2022 Aug 12, 2022	BUY	$41.26 - $51.35 $531,923 - $662,004	12,892 Added 4.23%	317,676 $14.1 Million
Q1 2022 May 13, 2022	BUY	$44.58 - $52.6 $671,151 - $791,893	15,055 Added 5.2%	304,784 $15.1 Million
Q4 2021 Feb 09, 2022	BUY	$45.82 - $56.9 $417,374 - $518,302	9,109 Added 3.25%	289,729 $14.8 Million
Q3 2021 Nov 12, 2021	SELL	$43.79 - $55.78 $900,191 - $1.15 Million	-20,557 Reduced 6.83%	280,620 $15.7 Million
Q2 2021 Aug 12, 2021	SELL	$36.86 - $44.5 $985,267 - $1.19 Million	-26,730 Reduced 8.15%	301,177 $12.9 Million
Q1 2021 May 14, 2021	BUY	$40.32 - $50.97 $842,567 - $1.07 Million	20,897 Added 6.81%	327,907 $13.7 Million
Q4 2020 Feb 25, 2021	BUY	$41.72 - $51.34 $12.8 Million - $15.8 Million	307,010 New	307,010 $14.3 Million

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $6.77M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Dimensional Fund Advisors LP with notifications on news.